Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286840 | 0.94 | CYP4F2 (0.35) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL6258518 | 0.86 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL6258085 | 0.86 | DGAT1 (0.37) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL6256870 | 0.85 | CYP4F2 (0.42) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL20375533 | 0.82 | CYP4F2 (0.43) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL5527551 | 0.81 | CYP4F2 (0.46) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL11438402 | 0.79 | CYP4F2 (0.39) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL19169471 | 0.78 | DGAT1 (0.39) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL27661776 | 0.77 | — | — | |
| SCHEMBL25884127 | 0.77 | HRH3 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004529069-A | — | — | 2004-09-24 | — | — | JP | claimed |
| EP-1351916-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002030863-A2 | ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018013-A1 | Ether compounds and compositions for cholesterol management and related uses | GPR119, PNLIP, NR1H2 | HRH3 4008/4885CYP4F2 561/4885CYP4A11 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.